Related Experiment Videos
Future directions with taxane therapy
1Department of Integrative Biology, Pharmacology and Physiology, University of Texas Medical School, Houston, USA.
Hematology/Oncology Clinics of North America
|March 18, 1999
Abstract:
The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.